CNS Cohen & Steers (CNS) Insider Trading, Ownership & Congress Trades
Financial Services · Investment advice · CIK 0001284812
Congress · 1
Insider buyers, 180 days
0
Funds added, last quarter
445
13F, latest reported quarter
What the filings say about CNS
Insiders, 180 days
-$1.2M net sold
3 sellers · 0% of sales under a 10b5-1 plan
Congress, 1 year
1 bought · 0 sold
Latest: purchase, 2025-10-30
Cohen & Steers insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, COHEN & STEERS, INC. insiders sold a net $1.2M of stock across 59 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Jul 26, 2024.
- The trade is 5.0% of the 22,146 shares held after it.
- No other insider sold within 30 days.
- 445 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Accounting Officer, SVP Dulik Elena sold about $91.5K of CNS on Jul 20, 2026; 445 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- 1 other insider sold within 30 days.
- 445 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Executive Vice President Noonan Daniel sold about $337.2K of CNS on Jun 16, 2026; 1 other insider sold within 30 days and 445 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on May 9, 2025.
- The trade is 15.7% of the 66,670 shares held after it.
- 1 other insider sold within 30 days.
- 445 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CIO Cheigh Jon sold about $753.4K of CNS on May 26, 2026, the largest insider sale at the company since 2025; 1 other insider sold within 30 days and 445 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Feb 11, 2026.
- The trade is 18.0% of the 55,675 shares held after it.
- No other insider sold within 30 days.
- 445 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: GC, Secretary, EVP POLI FRANCIS C sold about $657.3K of CNS on Feb 12, 2026; 445 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Sep 16, 2024.
- The trade is 6.6% of the 70,675 shares held after it.
- No other insider sold within 30 days.
- 445 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: GC, Secretary, EVP POLI FRANCIS C sold about $306.4K of CNS on Feb 11, 2026; 445 funds added in the latest 13F quarter.59 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$1.2M over 180 days
below 51% of Financial Services
Congress
1 member bought in the last year
the lowest in Financial Services
Funds
445 funds bought in last quarter
more than 90% of Financial Services
Revenue
+7.5% year over year
below 57% of Financial Services
Margin
27.6% net margin
more than 78% of Financial Services
Buybacks
$17.3M repurchased, FY to 2026-06-30
below 62% of Financial Services
Short interest
6.9% of the float short (float per yahoo 2026-10-27) · 6.2 days to cover · settled 2026-10-15
more than 62% of Financial Services
What changed in the last 30 days
Oct 28Insider selling stopped: no sales in 90 days after 3 in the prior 90
Why it matters
The absence is the signal: 3 sales in one 90-day window and none in the next is a change of behaviour, not a filing.
Watch CNS
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+4.4%12M
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns CNS: institutional holders (13F)
13F holdings, latest reported quarter
4,509,990 sh
$343.4M
23,360,710 sh
$326.2M
11,342,875 sh
$162.8M
1,701,955 sh
$129.6M
7,135,003 sh
$118.1M
Congress trades in CNS
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Bought 2025-10-30 · disclosed 19 days later
$1,001 - $15,000
Sold 2024-09-25 · disclosed 8 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
CNS planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
CNS mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Bluemonte Diversified Income ETF
$11.9M position · as of 2026-07-31
11.1%
Bluemonte Diversified Income ETF
$10.6M position · as of 2026-07-31
9.8%
Gabelli Financial Services Opportunities ETF
$2.6M position · as of 2026-06-30
5.2%
Rareview Dynamic Fixed Income ETF
$3.1M position · as of 2026-06-30
3.7%
DAVENPORT SMALL CAP FOCUS FUND
$22.7M position · as of 2026-06-30
3.6%
Nicholas Limited Edition, Inc.
$10.3M position · as of 2026-07-31
3.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Robert Steers
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2020
$5.1M
$7.2M
$3.4M
+23%
+28%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $1.2M sold by insiders over 180 days, 445 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade. Each figure is a federal filing, dated the day it went public.
CNS financials
Revenue growth
+7.5%
XBRL, annual
Net margin
27.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$583.9M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM CNS
| FY Dec 2025 | $556.1M |
| FY Dec 2024 | $517.4M |
| FY Dec 2023 | $489.6M |
| FY Dec 2022 | $566.9M |
| FY Dec 2021 | $583.8M |
| Jun 2026 | $152.7M |
| Mar 2026 | $145.6M |
| Dec 2025 | $143.8M |
| Sep 2025 | $141.7M |
| Jun 2025 | $136.1M |
| Mar 2025 | $134.5M |
| Dec 2024 | $139.8M |
| Sep 2024 | $133.2M |
At each fiscal year end
Single quarter
Net margin, TTM
+28.8%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM CNS
| FY Dec 2025 | +27.6% |
| FY Dec 2024 | +29.2% |
| FY Dec 2023 | +26.4% |
| FY Dec 2022 | +30.2% |
| FY Dec 2021 | +36.2% |
| Jun 2026 | +32.3% |
| Mar 2026 | +29.1% |
| Dec 2025 | +24.3% |
| Sep 2025 | +29.4% |
| Jun 2025 | +27.1% |
| Mar 2025 | +29.6% |
| Dec 2024 | +32.8% |
| Sep 2024 | +29.8% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$66.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM CNS
| FY Dec 2025 | -$126.4M |
| FY Dec 2024 | $85.0M |
| FY Dec 2023 | $115.0M |
| FY Dec 2022 | $57.5M |
| FY Dec 2021 | $240.2M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | $776.0K |
| Sep 2025 | $52.6M |
| Jun 2025 | -$69.8M |
| Mar 2025 | -$110.0M |
| Dec 2024 | $33.1M |
| Sep 2024 | $24.2M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity CNS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt CNS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+30.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity CNS
| FY Dec 2025 | +28.5% |
| FY Dec 2024 | +33.9% |
| FY Dec 2023 | +35.9% |
| FY Dec 2022 | +57.7% |
| FY Dec 2021 | +98.5% |
| Jun 2026 | +30.1% |
| Mar 2026 | +29.1% |
| Dec 2025 | +28.5% |
| Sep 2025 | +31.5% |
| Jun 2025 | +32.7% |
| Mar 2025 | +35.4% |
| Dec 2024 | +33.9% |
| Sep 2024 | +31.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+20.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets CNS
| FY Dec 2025 | +18.1% |
| FY Dec 2024 | +19.5% |
| FY Dec 2023 | +18.3% |
| FY Dec 2022 | +29.3% |
| FY Dec 2021 | +50.3% |
| Jun 2026 | +20.4% |
| Mar 2026 | +18.4% |
| Dec 2025 | +18.1% |
| Sep 2025 | +21.5% |
| Jun 2025 | +21.1% |
| Mar 2025 | +20.7% |
| Dec 2024 | +19.5% |
| Sep 2024 | +19.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital CNS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
assets or current liabilities not filed
Return on capital employed CNS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
21.89x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing CNS
| FY Dec 2025 | 21.14x |
| FY Dec 2024 | 31.09x |
| FY Dec 2023 | 29.13x |
| FY Dec 2022 | 18.61x |
| FY Dec 2021 | 21.46x |
| Jun 2026 | 23.43x |
| Mar 2026 | 20.71x |
| Dec 2025 | 21.14x |
| Sep 2025 | 20.57x |
| Jun 2025 | 23.92x |
| Mar 2025 | 26.23x |
| Dec 2024 | 31.09x |
| Sep 2024 | 35.80x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value CNS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+1.8%
TTM free cash flow over market value at close 2026-10-26
FCF yield CNS
| FY Dec 2025 | -3.9% |
| FY Dec 2024 | +1.8% |
| FY Dec 2023 | +3.1% |
| FY Dec 2022 | +1.8% |
| FY Dec 2021 | +5.4% |
| Jun 2026 | +1.7% |
| Mar 2026 | -2.1% |
| Dec 2025 | -3.9% |
| Sep 2025 | -2.8% |
| Jun 2025 | -3.2% |
| Mar 2025 | -0.6% |
| Dec 2024 | +1.8% |
| Sep 2024 | +2.1% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
6.90x
P/E over trailing EPS growth of 3%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing CNS
| FY Dec 2025 | 1,413,679,895,543,807.75x |
| FY Dec 2024 | 2.18x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 0.12x |
| Jun 2026 | 7.38x |
| Mar 2026 | n/a |
| Dec 2025 | 1,413,679,895,543,807.75x |
| Sep 2025 | 1.08x |
| Jun 2025 | 1.04x |
| Mar 2025 | 1.38x |
| Dec 2024 | 2.18x |
| Sep 2024 | 47.62x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $556.1M | $517.4M | $489.6M | $566.9M |
| Operating income | $177.7M | $172.9M | $164.5M | $215.9M |
| Net income | $153.2M | $151.3M | $129.0M | $171.0M |
| EPS (diluted) | 2.97 | 2.97 | 2.60 | 3.47 |
| Operating cash flow | -$120.4M | $96.7M | $172.0M | $61.7M |
| Cash | $145.5M | $183.0M | $187.4M | $247.4M |
| Buybacks | $28.4M | $21.1M | $21.5M | $26.8M |
| Dividends paid | $126.9M | $119.2M | $112.4M | $107.4M |
SEC XBRL, fiscal years, as known on 2026-10-28
CNS Stock Sonar score 5/7 axes
Find similar shapesCompareCNS ranks highest on profitability (89th percentile) and institutional and government (78th), and lowest on insider conviction (24th), among Financial Services peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
CNS filings, in plain words
Are Cohen & Steers insiders buying or selling CNS?
In the 180 days to 2026-10-28, Cohen & Steers insiders were net sellers, a net $1.2M across purchases and sales reported on Form 4, by 3 sellers.
Have members of Congress traded CNS?
Yes. In the year to 2026-10-28, 1 House member disclosed buying CNS and 0 House members disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2025-10-30.
Read the full summary
In the 180 days to 2026-10-28, Cohen & Steers insiders were net sellers of CNS, a net $1.2M across purchases and sales reported on Form 4 by 3 sellers. None of the 3 insider sales was flagged as made under a Rule 10b5-1 plan. In the year to 2026-10-28, 1 member of Congress disclosed buying CNS and 0 members disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2025-10-30. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
